Treatments for Asthma and Pre-Term Labor May Increase Risk of Autism-Spectrum Disorders in the Developing Fetus
New York, 2 December 2009 – Commonly prescribed beta 2 adrenergic agonist drugs for the treatment of asthma in pregnant women as well as pre-term labor may increase the incidence of autism-spectrum disorders, psychiatric pathology, cognitive problems and poor school performance in their children, according to a new study published in the December 2009 issue of theAmerican Journal of Obstetrics & Gynecology.
Beta 2 adrenergic agonist drugs as a class are widely used in obstetrics as tocolytics to inhibit or slow down labor and bronchodilators, but may act as functional and behavioral teratogens when given continuously in the mid to late second or early third trimesters. By correlating the basic science and clinical data, investigators observed that when given prenatally, these drugs can cause functional and behavioral disorders by permanently altering the balance of sympathetic and parasympathetic tone in the individual. Animal studies support the concept that in humans prenatal exposure to continuous high doses of beta 2 adrenergic agonists can permanently dysregulate signaling from the beta 2 adrenergic receptor.
Researchers show how sympathetic overactivity and disease are correlated, citing studies that show the association between in utero exposure to beta 2 adrenergic agonists in humans and later development of these conditions.
The authors also offer recommendations for safe practice in obstetrics in light of the teratogenic risk posed by beta 2 adrenergic agonists.
Writing in the article, Frank R. Witter, MD, , Johns Hopkins University School of Medicine and Johns Hopkins University Bloomberg School of Public Health, and co-authors state, “Given the risk of long-term neurophysiologic and behavioral impairment, the use of beta 2 adrenergic agonists should be limited to proven indications when alternate drugs are ineffective or unavailable and the risks of the untreated disease to the mother and fetus are greater than the risk of the beta 2 adrenergic agonist. Treatment duration should be as short as clinically feasible. Further ongoing surveillance of the use of these agents in pregnancy is needed to refine the parameters for their safe use in pregnancy. Future pharmacogenetics research is also needed to better characterize the highest risk group for teratogenesis from these agents.”
Echoing the concerns, Roberto Romero, MD, Chief, Perinatology Research Branch, Program Director for Obstetrics and Perinatology, Intramural Division, NICHD, NIH, DHHS and Associate Editor of the American Journal of Obstetrics & Gynecology, states that “The observations reviewed by the authors call for a re-examination of the commonly accepted safety of these agents during pregnancy.”
The article is “In Utero Beta 2 Adrenergic Agonist Exposure and Adverse Neurophysiologic and Behavioral Outcomes” by Frank R. Witter, MD, Andrew W. Zimmerman, MD, James P. Reichmann, MBA, and Susan L. Connors, MD. It appears in American Journal of Obstetrics & Gynecology, Volume 201, Issue 6 (December 2009) published by Elsevier.
# # #
Notes For Editors:
Full text of the article is available upon request. Contact Pamela Poppalardo at 732-238-3628 or firstname.lastname@example.org to obtain a copy. To schedule an interview with lead author Dr. Frank R. Witter please contact John Lazarou at 410-502-8902 or email at email@example.com.
Frank R. WITTER, MD, Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
Andrew W. ZIMMERMAN, MD, Department of Neurology and Developmental Medicine, Kennedy Krieger Institute and Departments of Neurology, Psychiatry and Pediatrics, Johns Hopkins University School of Medicine, and Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
James P. REICHMANN, MBA, American Home Patient, Brentwood, Tennessee
Susan L. CONNORS, MD, Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland and LADDERS Clinic of Mass General Hospital and Harvard Medical School, Boston, Massachusetts
About The American Journal of Obstetrics & Gynecology
The American Journal of Obstetrics & Gynecology, known as “The Gray Journal,” presents coverage of the entire spectrum of the field, from the newest diagnostic procedures to leading-edge research. The Journal provides comprehensive coverage of the specialty, including maternal-fetal medicine, reproductive endocrinology/infertility, and gynecologic oncology. It also publishes the annual meeting papers of several of its 7 sponsoring societies, including the Society for Maternal-Fetal Medicine and the Society of Gynecologic Surgeons.
The American Journal of Obstetrics & Gynecology's 2007 Impact Factor is 2.917 (previously 2.805) and it continues to be ranked #1 in citations in the Obstetrics & Gynecology category, according to the latest Journal Citation Reports® 2008, published by Thomson Reuters. Having moved up to the #7 position, the Journal’s standard of excellence and continued success can be attributed to the strong leadership of the Editors-in-Chief, Thomas J. Garite, MD, and Moon H. Kim, MD, and their outstanding nationally and internationally recognized editorial board and reviewers. The journal has also been recognized as one of the 100 most influential journals in Biology & Medicine over the last 100 years, as determined by the BioMedical & Life Sciences Division of the Special Libraries Association (2009).
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+1 732 238 3628